Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Quantum Materials ... volume production of photoactive quantum dots for use ... While offering numerous advantages for solar power generation, ... quantities of quantum dots with which to develop ... them from commercial utilization and acceptance. The company ...
(Date:10/1/2014)... FREMONT, Calif. , Oct. 1, 2014 ... ARDX ), a clinical-stage biopharmaceutical company focused ... announced positive results from its 371 patient ... patients with constipation-predominant irritable bowel syndrome (IBS-C).  ... and clinically meaningful improvement in IBS-C symptoms ...
(Date:10/1/2014)... October 1, 2014 Sophia Genetics, ... Sequencing (NGS) data analysis, today launches a unique CFTR ... analysis in a single NGS experiment. The CE-IVD marked ... of variants in a single NGS experiment with clinical ... not been possible to simultaneously analyse all relevant CFTR ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... , ... Food and Drug Administration (FDA) has notified health professionals, and ... -- from the use of negative pressure wound therapy (NPWT). ... therapy devices can help in the healing and closure of ...
... , ... a leading provider of software solutions to optimize clinical ... release of StudyOptimizer 4, the latest iteration of its ... pharmaceutical companies, DecisionView,s flagship product now includes advanced historical ...
Cached Medicine Technology:Negative Pressure Wound Devices Draw FDA Notice, Advice 2DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3
(Date:10/1/2014)... 01, 2014 Innovations announces the upcoming ... broadcast on Monday, October 20, 2014 at 7:30 a.m. ... will go behind the scenes to learn about Break ... will explore the practical help and information Break the ... the warning signs of abuse, how to navigate the ...
(Date:10/1/2014)... 01, 2014 Anti Aging Clinic (AntiAgingClinic.ca), ... rejuvenating destination of choice, is announcing a discounted cost ... to December. , “We’re doing this because we want ... our top skin clinic in Toronto,” says Dr. Brian ... much at Anti Aging Clinic, including laser facials, genesis ...
(Date:10/1/2014)... at the occasion of the Leishmaniasis East Africa ... and international leishmaniasis experts, results of a pharmacovigilance ... plan, carried out by MSF, DNDi, and ... were presented to key decision makers in order ... with the combination of Sodium Stibogluconate and Paromomycin ...
(Date:10/1/2014)... HILLS, CA (PRWEB) October 01, 2014 ... Reshad will speak to a group of dental specialists ... in the northern Spain city of Oviedo. Dr. Reshad ... prosthodontist and lecturer with clients on two continents, will ... complex and aesthetic full mouth reconstruction. , “These specialists ...
(Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
Breaking Medicine News(10 mins):Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... , , Gates ... and a Bright One , SEATTLE , Jan. ... & Melinda Gates Foundation, today released his second annual letter -- ... innovation impacts priorities of the foundation. , Gates is optimistic that, ...
... or ambidextrous, are more likely to have mental health, ... left-handed children, according to a new study published today ... researchers behind the study, from Imperial College London and ... teachers and health professionals to identify children who are ...
... shows it may have prevented, treated eye infections , ... makeup worn thousands of years ago by Queen Nefertiti ... to enhance beauty alone: New research suggests that the ... disease. , Some ancient Egyptians thought their lead-based ...
... ... billing and practice management services nationwide, announces today its’ addition of three exceptional leaders ... as Client Managers, while Jamie Hays has come aboard as the Client Accounting Manager. ... Columbus, OH ...
... , ... have identified brain networks damaged in Parkinson’s disease have new evidence that these systems ... network appear to respond in a last ditch attempt to rescue the brain. ... Manhasset, NY (Vocus) ...
... , SCOTTSDALE, Ariz. , Jan. 22 ... real estate investment trust, announced the execution of a purchase ... office portfolio located in Atlanta, Georgia for approximately ... to a number of conditions. , The medical office portfolio ...
Cached Medicine News:Health News:Bill Gates Releases Annual Letter 2Health News:Bill Gates Releases Annual Letter 3Health News:Mixed-handed children more likely to have mental health, language and scholastic problems 2Health News:Mixed-handed children more likely to have mental health, language and scholastic problems 3Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 2Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 3Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 2Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... Plus™ Uncuffed Endotracheal Tube w. FlexiSlip™ Stylet, Murphy ... A quality Rusch endotracheal tube with a preloaded ... time and storage space. The stylet has a ... is designed with a soft distal tip to ...
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Medicine Products: